Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mushroom-Derived drug targets kidney cancer in dialysis patients

NCT ID NCT05287945

First seen Jan 10, 2026 · Last updated May 20, 2026 · Updated 19 times

Summary

This early-stage trial tests a drug called orellanine in people with advanced kidney cancer who are also on dialysis due to end-stage kidney disease. The goal is to see if the drug is safe and can shrink tumors. Participants must have tried standard treatments without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karolinska University Hospital

    RECRUITING

    Stockholm, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • START Lisbon - Hospital de Santa Maria Av

    RECRUITING

    Lisbon, 1649-035, Portugal

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Stanford

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas - MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 63130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.